Finance

Lists
2196:HKG
Shanghai Fosun Pharmaceutical (Group) Ord Shs H
17,11 HKD
-0,23%
(-0,040) 1D
16-окт., 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 2196...
Open
17,32 HKD
High
17,55 HKD
Low
16,88 HKD
Mkt. cap
66,54 млд
Avg. vol.
3,62 млн
Volume
2,25 млн
Dividend
2,63%
Quarterly dividend
0,11 HKD
Ex-dividend date
2026-ж., 27-июл.
P/E ratio
11,33
52-wk high
24,84 HKD
52-wk low
14,90 HKD
EPS
1,51 HKD
Shares outstanding
551,94 млн
No. of employees
41 миң
Open
17,32 HKD
High
17,55 HKD
Low
16,88 HKD
Mkt. cap
66,54 млд
Avg. vol.
3,62 млн
Volume
2,25 млн
Dividend
2,63%
Quarterly dividend
0,11 HKD
Ex-dividend date
2026-ж., 27-июл.
P/E ratio
11,33
52-wk high
24,84 HKD
52-wk low
14,90 HKD
EPS
1,51 HKD
Shares outstanding
551,94 млн
No. of employees
41 миң
News stories
From web sources and news partners
Profile
Shanghai Fosun Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company. It is mostly owned by Fosun International. As of 2018, the A shares of the company is a constituent of SSE 180 Index as well as its sub-index SSE MidCap Index. The company was ranked 1,840th in 2020 edition of the Forbes Global 2000, a list of top listed companies of the world. Wikipedia
About Shanghai Fosun Pharmaceutical (Group) Ord Shs H
CEOLiu Yi | Wen Deyong
Employees40,7 миң
Founded1994
Headquarters-
SectorPharmaceutical industry
Last report
2026-ж., 25-авг.
Fiscal period
Q2 2026
- / -
Revenue / Est. (CNY)
10,37 млд / 10,66 млд
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
9,88 млд
12,27 млд
10,07 млд
10,37 млд
Cost of goods sold
5,08 млд
5,65 млд
5,07 млд
5,23 млд
Cost of revenue
5,08 млд
5,65 млд
5,07 млд
5,23 млд
Research and development expenses
1,01 млд
1,28 млд
896,79 млн
1,19 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,10 млд
4,44 млд
3,27 млд
3,35 млд
Operating expense
4,04 млд
5,92 млд
4,19 млд
4,63 млд
Total operating expenses
9,12 млд
11,57 млд
9,26 млд
9,86 млд
Operating income
758,38 млн
699,05 млн
813,78 млн
505,27 млн
Other non operating income
-116,85 млн
107,33 млн
2,03 млн
-13,28 млн
EBT including unusual items
1,12 млд
1,27 млд
1,36 млд
1,23 млд
EBT excluding unusual items
1,49 млд
1,10 млд
1,21 млд
1,07 млд
Income tax expense
162,98 млн
82,80 млн
277,92 млн
159,73 млн
Effective tax rate
14,57%
6,50%
20,47%
13,00%
Other operating expenses
-92,19 млн
117,57 млн
19,04 млн
74,01 млн
Net income
821,33 млн
847,27 млн
870,83 млн
850,64 млн
Net profit margin
8,31%
6,91%
8,64%
8,20%
Earnings per share
-
-
-
-
Interest and investment income
1,05 млд
732,13 млн
689,67 млн
938,86 млн
Interest expense
-321,25 млн
-291,32 млн
-296,51 млн
-310,88 млн
Net interest expenses
727,28 млн
440,80 млн
393,16 млн
627,98 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,39 млд
1,47 млд
1,59 млд
1,24 млд
Gain or loss from assets sale
2,12 млн
-69,35 млн
-
-195,23 миң
AI content may include mistakes. Learn more
Google колдонмолору